6,650 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Hemenway Trust Co LLC

Hemenway Trust Co LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,650 shares of the biopharmaceutical company’s stock, valued at approximately $487,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Etesian Wealth Advisors Inc. raised its holdings in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. raised its holdings in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares in the last quarter. Steph & Co. raised its holdings in Gilead Sciences by 1.9% in the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after purchasing an additional 142 shares in the last quarter. Finally, First Affirmative Financial Network raised its holdings in Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD traded up $1.22 during trading hours on Thursday, reaching $69.97. The company’s stock had a trading volume of 9,595,036 shares, compared to its average volume of 7,507,853. The firm’s 50-day moving average price is $66.32 and its 200-day moving average price is $71.87. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a market capitalization of $87.17 billion, a price-to-earnings ratio of 194.36, a PEG ratio of 2.87 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the firm earned $1.37 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.40%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Analyst Ratings Changes

GILD has been the subject of several analyst reports. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, April 24th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a report on Monday. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Monday, July 1st. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $84.00.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.